Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICE says no to breast cancer treatment Halaven

July 20, 2011
Sales and Marketing Eisai, Halaven, NICE

Eisai’s Halaven has been rejected by NICE in draft guidance for locally advanced or metastatic breast cancer. Halaven (eribulin) is …

News

Government seeks to salvage pharma pricing reforms

July 19, 2011
Sales and Marketing NICE, value-based pricing

The government is pushing ahead with plans to introduce value-based pricing in 2014, despite acknowledging the new system still requires …

News

NICE decides laser treatment better than Lucentis

July 18, 2011
Sales and Marketing Lucentis, NICE, Novartis

Novartis says it is “disappointed” with health watchdog NICE’s decision not to recommend Lucentis for the treatment of eye problems …

News

The changing fortunes of NICE and health secretaries

July 15, 2011
Sales and Marketing NICE

You might not have noticed, but the government has performed a major U-turn. No, I don’t mean the NHS reform …

Feature

UK pricing reform derailed

July 15, 2011
Sales and Marketing NICE, PPRS, value-based pricing

Plans to revolutionise the pricing of medicines in the UK look to be another casualty in the Department of Health’s …

News
Roche's Tarceva (erlotinib)

Tarceva fails to win NICE backing

June 30, 2011
Sales and Marketing NICE, Tarceva

NICE has decided not to recommend Roche’s Tarceva because of uncertainty over how long the lung cancer drug can extend …

News

NICE gains expanded role alongside value-based pricing

June 21, 2011
Sales and Marketing NHS reforms, NICE, value-based pricing

NICE will be given a wider remit to oversee social care and its guidance used alongside value-based pricing as part …

News

NICE backs Celgene’s thalidomide and Janssen’s Velcade

June 21, 2011
Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma

Celgene’s thalidomide and Janssen-Cilag’s Velcade have been given the thumbs up by NICE as a treatment for a cancer that …

News

NICE guideline helping to cut referrals

June 20, 2011
GSK, NICE, bph

A NICE guideline on treating lower urinary tract symptoms (LUTS) in men is helping to cut referrals to urologists, thereby …

News
Cost-effectiveness assessment body NICE

NICE reprieved by government U-turn

June 20, 2011
Sales and Marketing Health and Social Care Bill, NICE, value-based pricing

The government has performed an unexpected U-turn by allowing NICE to retain its powers to decide which new drugs the …

News

NICE thumbs up for Allergan’s Ozurdex

June 9, 2011
Sales and Marketing Allergan, BRVO, CVRO, NICE, Ozurdex

In draft guidance NICE has recommended the use of Allergan’s eye treatment Ozurdex.NICE’s final decision on Ozurdex (dexamethasone) is expected …

News

NICE to appraise hep C drugs Victrelis and telaprevir

May 26, 2011
Sales and Marketing Brinavess, Ilaris, NICE, Victrelis, Xarelto, Zytiga, telaprevir

NICE’s next round of drug appraisals is set to include two new hepatitis C drugs – Merck Sharpe and Dohme’s …

News
Roche's MabThera’s (rituximab)

NICE U-turn on Roche’s MabThera

May 25, 2011
Sales and Marketing MabThera, NICE, Roche

NICE has provisionally recommended Roche’s MabThera as a maintenance therapy for blood cancer patients. The new draft guidance backs MabThera’s …

News

Price concession helps change NICE’s mind on Simponi

May 13, 2011
Sales and Marketing NICE, Simponi, TNF, merck sharp and dohme

NICE has provisionally recommended Merck Sharp & Dohme’s Simponi for rheumatoid arthritis alongside other drugs in the TNF inhibitor class. …

News
Blog footer

Digital Pharma: NICE puts guidance into online pathways

May 11, 2011
Sales and Marketing Digital Pharma blog, NICE

NICE has launched a new online tool that groups its guidance into user-friendly flowcharts to show care pathways. NICE Pathways …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026